Welcome to our dedicated page for TRXC news (Ticker: TRXC), a resource for investors and traders seeking the latest updates and insights on TRXC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TRXC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TRXC's position in the market.
Asensus Surgical, Inc. (formerly TransEnterix, Inc.) has officially completed its name and ticker symbol change, effective March 5, 2021. The company's stock will now trade under the new ticker symbol ASXC on the NYSE American, replacing the previous TRXC symbol. This change reflects Asensus Surgical's commitment to digitizing surgical processes through its Senhance® Surgical System, enhancing surgical outcomes via innovative technologies. No action is required from current shareholders regarding this change.
Asensus Surgical (NYSE American: TRXC) announced its scheduled release of fourth quarter and fiscal year 2020 financial results on March 11, 2021, after market close. A conference call will follow at 4:30 p.m. ET, where the financial results will be discussed. Asensus focuses on pioneering Performance-Guided Surgery through its Senhance Surgical System, which integrates digital technology to improve surgical outcomes and reduce variability. Their innovative approach is available in multiple countries including the US and EU.
Asensus Surgical (NYSE American: TRXC) has received FDA clearance to expand the indications for its Senhance Surgical System into general surgery, marking a significant milestone for the company. This digital laparoscopic platform utilizes machine learning and offers unique features such as haptic feedback and eye-tracking camera control. The expansion allows the system to be applied in over 2.7 million general surgical procedures annually in the US, catering to complex surgeries like reflux and obesity treatments. CEO Anthony Fernando highlights the move as pivotal for growth and clinical applications.
Asensus Surgical, Inc. (NYSE American: TRXC) announced participation in the H.C. Wainwright Virtual Global Life Sciences Conference on March 9-10, 2021. CEO Anthony Fernando and CFO Shameze Rampertab will present, with the on-demand presentation available starting March 9 at 7:00 am ET on the company's investor relations page. Asensus is leading in Performance-Guided Surgery, utilizing the Senhance® Surgical System, which enhances surgical precision and reduces variability using advanced technologies like machine vision and deep learning.
TransEnterix, Inc. will rebrand as Asensus Surgical, Inc., effective March 5, 2021, with a new ticker symbol ASXC. This change aims to reflect the company's evolution towards integrating computer vision and machine learning in surgery. The Senhance® Surgical System, used in over 4,000 procedures, offers advanced features including haptic feedback and 3D visualization. CEO Anthony Fernando emphasized the goal of creating performance-guided surgery through augmented intelligence. The name change also includes a new logo and website launch, enhancing the company's identity.
TransEnterix, Inc. (NYSE American: TRXC) has partnered with the Amsterdam Skills Centre (ASC) to enhance surgical training across Europe for its Senhance® Surgical System. This partnership aims to support both basic and advanced training, and the ASC will serve as a hub for technology and clinical development studies. The Senhance Surgical System offers innovative features such as haptic feedback and robotic precision to minimize healthcare costs while improving surgical outcomes. This collaboration reflects TransEnterix's commitment to expanding its presence in the European market.
TransEnterix, a medical device company (NYSE American: TRXC), announced a virtual Investor Day on February 23, 2021, at 11:00 AM ET. The event will focus on updates regarding the Senhance Surgical System and its role in Digital Laparoscopy, alongside corporate strategy insights. President Anthony Fernando emphasized significant progress in 2020 and future potentials of Digital Laparoscopy. Participants can register for the webcast on the company's investor relations page, with archived access available later.
TransEnterix, Inc. (NYSE American: TRXC) successfully closed a public offering of 26,545,832 shares at $3.00 per share, raising approximately $79.64 million. The proceeds will be allocated to general corporate purposes, including working capital and product development. H.C. Wainwright & Co. was the book-running manager for the offering. The company expects that combined with previous offerings, its cash will be sufficient to fund operations into 2024.
TransEnterix, Inc. (TRXC) increased its common stock offering to 23,083,333 shares at $3.00 per share, aiming to raise approximately $69.25 million. The offering, set to close on January 29, 2021, also includes an option for underwriters to purchase an additional 3,462,499 shares. Proceeds will support general corporate purposes, including research and development. This offering is conducted under effective SEC registration statements, ensuring compliance with regulatory standards.
TransEnterix has entered an underwriting agreement with H.C. Wainwright & Co. to sell 8,333,334 shares at $3.00 each, aiming to raise approximately $25 million in gross proceeds. The offering is expected to close around January 29, 2021. The net proceeds will be used for general corporate purposes, including R&D activities. Additionally, the underwriter holds a 30-day option for purchasing 1,250,000 extra shares. The offering is made under a previously effective registration statement with the SEC.
